Articles related to CANCER SCREENING

Early detection remains paramount – 90% of early-stage colon cancer patients survive at least 5 years after diagnosis, emphasizing the critical importance of timely screening.

In the BLUE-C trial, Cologuard Plus demonstrated a 93.9% sensitivity for colorectal cancer detection, significantly outperforming the 67.3% sensitivity of FIT.

AI-assisted diagnosis of lung cancer showed 87% sensitivity and 87% specificity in a meta-analysis, suggesting potential for improved accuracy in interpreting chest CT scans.

In a population-based trial, MRI-targeted biopsy significantly reduced the detection of clinically insignificant prostate cancer compared to systematic biopsy, without increasing the risk of advanced cancer detection. These findings support the use of MRI-targeted biopsy as a more efficient and safer screening method.

The FDA’s new mandate requires all mammography facilities to inform women about their breast density, recognizing its significance in cancer risk and detection challenges.

Medical errors are now recognized as the third leading cause of death in the US, emphasizing the urgent need for improved safety measures in healthcare settings.